Company Overview and News


Add PIRS
to your dashboard

Headline News

Pieris Pharmaceuticals' (PIRS) CEO Stephen Yoder on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Greetings, and welcome to the Pieris Pharmaceuticals Third Quarter 2017 Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow a formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Allan Reine. Please go ahead, sir. (41-3)

Pieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2017, and Provides Corporate Update

2017-11-08 marketwired
BOSTON, MA--(Marketwired - November 08, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, today reported financial results for the third quarter of 2017 and provided a corporate update: (56-0)

What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?

2017-11-07 zacks
Merck’s revenues were driven by sales growth in its Healthcare and Life Science segment in the first half of the year. We expect the positive trend to continue this quarter. Meanwhile, the company is streamlining its Healthcare business to focus on its pipeline of innovative medicines. (65-0)

Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?

2017-11-07 zacks
We expect Puma Biotechnology, Inc. (PBYI - Free Report) to beat estimates when it reports third-quarter 2017 results on Nov 9 after market close. (71-0)

BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?

2017-11-07 zacks
BioDelivery Sciences International, Inc. (BDSI - Free Report) is scheduled to report third-quarter 2017 results on Nov 9 after market close. Last quarter, the company delivered a negative earnings surprise of 8%. (87-0)

Pieris Pharmaceuticals to Host Third Quarter 2017 Investor Call and Corporate Update on November 9, 2017

2017-11-02 marketwired
BOSTON, MA--(Marketwired - November 02, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that will host a Q3 2017 Investor Call on Thursday, November 9, 2017 at 10:00 AM (EST) to discuss financial results and provide a corporate update. (41-0)

Pieris Pharmaceuticals to Present at Investor Conferences in November

2017-11-01 marketwired
BOSTON, MA--(Marketwired - November 01, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that members of the management team will present at the following upcoming investor conferences: (41-0)

Stellar BioSciences For Value Investors

2017-10-17 seekingalpha
The biotech sector has been red hot with key firms gaining substantial value for investors. Among those companies stands out Spectrum Pharmaceuticals (NASDAQ:SPPI), a firm that focuses on the innovation and commercialization of therapeutics to treat cancers. Since fellow Seeking Alpha, Decision Analytics (“DA”), initiated the buy recommendation on Spectrum, the stock soared by more than 34%. With more than a decade of experience investing in the bioscience sector, DA also authored a number of scientific publications. (272-5)

Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development

2017-10-12 marketwired
BOSTON, MA--(Marketwired - October 12, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced that it has appointed Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development, effective today. Dr. Bruns is an accomplished physician and brings to Pieris a wealth of oncology and hematology experience, a deep science background, and a strong clinical development acumen. (41-0)

New Strong Sell Stocks for October 11th

2017-10-11 zacks
Flowserve Corporation (FLS - Free Report) is a designer, manufacturer and distributor of industrial flow management equipment. The Zacks Consensus Estimate for its current year earnings has been revised 2.1% downward over the last 30 days. (269-2)

Best Performing Stocks YTD Through Q3 2017

2017-10-03 seekingalpha
Below is a list of the 40 best-performing Russell 3,000 stocks on a year-to-date basis through the third quarter of 2017. You'll notice that a bulk of the names on the list of biggest winners are from the Biotech space. Dynavax Tech (NASDAQ:DVAX) ranks first with a YTD gain of 444%. Straight Path (NYSEMKT:STRP) ranks second at +432.79% but it's in the process of getting acquired after a bidding war for the company's valuable spectrum. (179-9)

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343

2017-10-02 marketwired
BOSTON, MA--(Marketwired - October 02, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, today announced that the first patient has been dosed in the Company's Phase I clinical trial of PRS-343, its lead proprietary immuno-oncology drug candidate. (41-0)

Biotech Stocks on Investors' Radar -- Neothetics, Pieris Pharma, and Repros Therapeutics

2017-09-27 prnewswire
If you want a Stock Review on NEOT, PIRS, or RPRX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Tuesday, September 26, 2017, US markets saw three out of nine sectors finishing the day in green, five in red, and one in neutral territory. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 6,380. (170-5)

Pieris Pharmaceuticals to Present at the LEERINK Partners Roundtable Series on Thursday, September 28 at 9:30 AM ET

2017-09-26 marketwired
BOSTON, MA--(Marketwired - September 26, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that President and CEO Stephen Yoder will present a corporate overview and meet with investors at the LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology. (41-1)

Stock Research Report

Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Pieris' pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Each of its development programs focus on the following:

  • 300-Series oncology drug candidates are multispecific Anticalin®-based proteins designed to engage immunomodulatory targets and consist of a variety of multifunctional biotherapeutics that genetically link antibody with one or more Anticalin proteins, thereby constituting...
Click for full article
CUSIP: 720795103